The results of an important Ninlaro (ixazomib) clin­i­cal trial have been published in a leading medical journal.

The "TOURMALINE-MM1" trial was instrumental in gaining Ninlaro ap­proval in the United States as a new treat­ment for multiple myeloma. The Phase 3 trial tested whether adding Ninlaro to Revlimid (lena­lido­mide) and dexa­metha­sone is safe and im­proves treat­ment out­comes in patients with re­lapsed multiple myeloma

Up until now, only limited results of the TOURMALINE-MM1 trial have been publicly avail­able. Some can be found in Ninlaro's pre­scrib­ing in­­for­ma­tion. …